NICE Decision On Arthritis Opens Door For Biosimilars
UK Recommends Treating Moderate Rheumatoid Arthritis With Three Biologic Molecules
A decision by the UK’s NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.
You may also be interested in...
A more efficient system to pave a path to market for biosimilars is needed in the UK, the British Biosimilars Association has urged, as it welcomed recent moves to broaden the use of adalimumab, etanercept and infliximab for treating moderate as well as severe rheumatoid arthritis.
A combination of factors – including recent moves in the UK to broaden access to biosimilars for rheumatoid arthritis patients, as well as the new MHRA pathway for biosimilars and a growing call for global regulatory alignment – are contributing to a “biosimilar Zeitgeist” that could see long-in-the-making change coming for the industry, according to Sandoz CEO Richard Saynor.
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.